PharmaVentures supports GeneCode’s successful record-breaking submission to European Innovation Council Accelerator

Press Releases

London, UK, 11 July 2023: PharmaVentures congratulates GeneCode on their successful application to the European Innovation Council (EIC) Accelerator, securing a groundbreaking funding package of €16 million. The funding comprises €1.7 million in grant funding and €14.3 million in equity investments, marking a significant milestone as the largest funding ever received by an Estonian company under the EIC Accelerator programme.

PharmaVentures is pleased to have supported GeneCode’s highly successful application by providing comprehensive market analysis, deal benchmarking, and asset valuation services.

Stephen Waterman, Managing Director at PharmaVentures, emphasised the importance of a specialised approach, stating, “It is often easy to generalise when discussing larger, unaddressed markets, such as disease modifying therapies for Parkinson’s. However, GeneCode’s achievement demonstrates the tangible value that can be derived from a thorough, detailed, and specific analysis. At PharmaVentures, we pride ourselves on our commitment to delivering in-depth insights that help drive our clients’ success.”

GeneCode’s CEO, Paavo Pilv, expressed his approval of the PharmaVentures analysis, stating, “PharmaVentures has been exceptional throughout the entire process. We greatly appreciated their meticulous care and attention to detail, which is not always found in such collaborations. We look forward to continuing the collaboration with PharmaVentures.”

PharmaVentures recognises the significance of the EIC Accelerator, a highly respected programme under Horizon Europe, supporting cutting-edge innovation and growth in Europe’s entrepreneurial ecosystem.

GeneCode’s groundbreaking treatment for Parkinson’s disease addresses a critical need, as the disease affects over 10 million people worldwide. While current treatments primarily focus on symptom relief, GeneCode’s GDNF mimetic has demonstrated the potential to slow down disease progression, offering new hope for patients. The secured funding will enable GeneCode to accelerate development, aiming to achieve IND-ready status and initiate clinical trials.

– Ends –

For further information, please contact:

Lisa Holloway
Senior Marketing Manager
lisa@pharmaventures.com

Phone: +44 (0) 1865 332700

 

About PharmaVentures

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances.

For over 30 years, PharmaVentures has acted as advisor on over 1000 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning.

PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures’ services include:

  • M&A (divestments, mergers, acquisitions, and strategic transactions)
  • Licensing (in and out licensing)
  • Fundraising Support
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Valuations (licensing, M&A, and fundraising)
  • Pricing and Market Access

PharmaVentures is based in London, UK, and employs over 30 professionals and has associates in Europe and Asia-Pacific.

NOTE: This Press release is issued by PharmaVentures Limited, whose wholly owned subsidiary PharmaVentures Capital Limited is authorised and regulated by the Financial Conduct Authority (741356). This communication is for information purposes only and does not constitute an offer or solicitation to purchase or engage in any investment products, securities or services and should not be deemed as such.

For more details, visit https://www.pharmaventures.com

Follow us on LinkedIn: https://www.linkedin.com/company/pharmaventures/

About GeneCode

GeneCode is a private pharmaceutical development company focused on the development of disease modifying therapeutics to combat neurodegeneration. The company was founded in 1998 in Estonia. The GDNF Mimetics platform leverages the disease-modifying properties of GDNF to small molecules with drug-like properties.

More information: www.GeneCode.com
Genecode’s press release can be found here
Genecode website: https://www.genecode.com/news/

4 Common Mistakes in Partnering

PharmaVentures Podcasts

PharmaVentures Podcast Series, Edition 9

 

Listen as Fintan Walton, PharmaVentures’ CEO and Founder, discusses the 4 common mistakes being made in partnering and how to avoid them.

Fintan provides insight into how to achieve successful deal outcomes by avoiding risks along the clinical, commercial and regulatory pathway, and what fact-based data you need to get your drug to market with the right partner at the right price.

 

About the Interviewee:

Fintan Walton is the Founder and CEO of PharmaVentures. He has over 30 years’ experience helping clients achieve success in deal making.

Over a period of three decades, he has built it into a global player in supporting transactions for blue chip corporations and emerging innovator corporations. In that time, the firm has delivered more than 1,000 transaction related assignments for companies in 38 countries.

 

About the Presenter:

Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.

During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

The Importance of Pricing and Market Access in Licensing, Partnering and Early-Stage Development

PharmaVentures Podcasts

PharmaVentures Podcast Series, Edition 8

 

Listen as Ralph Hughes, PharmaVentures’ Pricing and Market Access expert, talks with Adrian Dawkes about how you can reduce the risk when you want to get your asset onto the market and get ahead of the competition.

  • Understanding incentives, perspectives and funding flows can lead to better pricing and development strategies.
  • Understanding payer perspectives can help you define market positioning and pricing.
  • Targeting drug development at payers, as well as the regulators, can ensure adoption.
  • Payers can become advocates, not blockers, given the right data and narrative.
  • How combining pricing and market access with valuation work can increase investor confidence.

 

About the Presenter:

Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.

During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

 

About the Interviewee:

Ralph Hughes is a Vice President at PharmaVentures with experience in Pricing and Market Access and Commercial and Business Development.

He has held various roles in the pharmaceutical industry. For Mundipharma, he developed the commercial and market access strategy for development and launch assets. At Pfizer, he developed market access and pricing strategies across the globe and across multiple disease areas for both early, late stage and in-market assets. He has delivered marketing campaigns, global forecasts, HTAs, pricing strategies, real world data studies, and economic models; through this, Ralph has a deep understanding of what it takes to commercialise an asset in the pharmaceutical industry. He holds a MSc in Public Health and Health Economics from the London School of Hygiene and Tropical Medicine and a BSc in Biomedical Sciences from Newcastle.

 

PharmaVentures recruits new Managing Director to join its corporate advisory team

Press Releases

Dr Andrew Guise joins to support companies, private equity, and investors maximising value by executing strategically sound M&A and Fundraising transactions.

London, UK, 29 March 2023: PharmaVentures is pleased to announce the appointment of Andrew Guise as a Managing Director to its corporate advisory team. 

Andrew is a highly accomplished executive with over 30 years of experience in finance, business development, and leadership. At UBS, he worked on over $4bn of transactions, before moving into Biotech Management, and then Venture Capital for East Hill Capital. He floated ThromboGenics in Belgium as CBO/CFO and was latterly CEO of Purity Health. He has led projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.

“I am honoured to join PharmaVentures,” said Dr Guise “We are seeing a shift from financing and capital raises towards M&A, as CEOs and investors seek alternative strategies for success. Unlocking these deals and maximising value requires deeper technical expertise, long standing relationships, and the ability to invest time in seeking out options. This is where PharmaVentures excels.”

Dr Fintan Walton, Founder and CEO of PharmaVentures, said, “We are delighted to welcome Andrew to PharmaVentures. He has over 30 years’ experience in all areas of healthcare including general strategy, fundraising, innovation, exit strategy and M&A.”

Andrew has held Board/C suite roles in a number of public and private life science companies across multiple sectors. If you would like to learn more, contact Dr Guise at andrewg@pharmaventures.com

Andrew Guise joins PharmaVentures

– Ends –

For further information, please contact:

Lisa Holloway
Senior Marketing Manager
lisa@pharmaventures.com

Phone: +44 (0) 1865 332700 

About PharmaVentures 

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. 

For over 30 years, PharmaVentures has acted as advisor on over 1000 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning.

PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest. 

PharmaVentures’ services include: 

  • M&A (divestments, mergers, acquisitions, and strategic transactions)
  • Licensing (in and out licensing)
  • Fundraising Support
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Valuations (licensing, M&A, and fundraising)
  • Pricing and Market Access 

PharmaVentures is based in London, UK, and employs over 30 professionals and has associates in Europe and Asia-Pacific. 

NOTE: This Press release is issued by PharmaVentures Limited, whose wholly owned subsidiary PharmaVentures Capital Limited is authorised and regulated by the Financial Conduct Authority (741356). This communication is for information purposes only and does not constitute an offer or solicitation to purchase or engage in any investment products, securities or services and should not be deemed as such.

For more details, visit https://www.pharmaventures.com

Follow us on LinkedIn: https://www.linkedin.com/company/pharmaventures/

 

 

Medical Device and In Vitro Diagnostic Regulations are changing. How will you be affected?

PharmaVentures Podcasts

PharmaVentures Podcast Series, Edition 7

 

Listen as Ben Jacoby, Regulatory Expert, talks with Adrian Dawkes about the transition to the new regulations in Europe and UK:

  • Can existing products continue to be sold?
  • What will global manufacturers need to do?
  • What is the impact for companion diagnostics being used alongside drugs in clinical trials?
  • How is the environment in Great Britain different, and what does this mean for innovators?
  • What’s the impact for patients?

A rare opportunity to hear from one of the most experienced regulatory advisors in this important space.

 

About the Presenter:

Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.

During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

 

About the Interviewee:

Ben Jacoby is an experienced regulatory consultant who has worked with clients in the diagnostic, medical device and pharmaceutical industries to help them bring innovative products to market. He provides regulatory and strategic guidance on EU, UK and US issues to clients.

Ben has worked on European and UK medical device regulation.

Core competencies include: technical files, Clinical studies; EU and UK legislation including IVD’s, companion diagnostics and medical devices; EU legislative requirements for instruments; and classification of devices. With more than 25 years of experience in regulatory affairs, he was European-authorised representative at Ortho-Clinical Diagnostics (a Johnson & Johnson company at the time).

Ben has a PhD in Biochemistry from the University of London.